Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Yang, C.-F.
Right arrow Articles by Ong, C.-N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, C.-F.
Right arrow Articles by Ong, C.-N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 21, No. 12, 2237-2243, December 2000
© 2000 Oxford University Press

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Inhibition of ebselen on aflatoxin B1-induced hepatocarcinogenesis in Fischer 344 rats

Cheng-Feng Yang, Jin Liu, Shanthi Wasser1, Han-Ming Shen, Carolyn Eng-Looi Tan1 and Choon-Nam Ong2

Department of Community, Occupational and Family Medicine, National University of Singapore and
1 Department of Pediatric Surgery, KK Women's and Children's Hospital, Singapore

Aflatoxin B1 (AFB1), a potent hepatocarcinogen, enhances ROS formation and causes oxidative DNA damage, which may play a role in its carcinogenicity. We have demonstrated recently that ebselen, an organic selenium compound, protects against the cytotoxicity of AFB1 through its antioxidant capability. The present study was designed to investigate the effect of ebselen on AFB1-induced hepatocarcinogenesis in an animal model. Fischer 344 rats were first treated with either deionized water or ebselen (5 mg/kg, 5 days/week) via gavage for 4 weeks, then given AFB1 (0.4 mg/kg, gavage, once a week) or AFB1 plus ebselen (5 mg/kg, 5 days/week) for another 24 weeks. The results showed that the hepatocarcinogenicity of AFB1 in rats was significantly reduced by ebselen treatment as indicated by a decrease in: (i) serum {gamma}-glutamyl transpeptidase activity; (ii) expression of mRNAs of liver {alpha}-fetoprotein and the placental form of glutathione S-transferase (GST-P); and (iii) the area and mean density of staining of liver GST-P foci. Ebselen treatment significantly reduced the formation of hepatic AFB1–DNA adducts and 8-hydroxydeoxyguanosine caused by AFB1 exposure. These findings suggest that ebselen can inhibit the carcinogenicity of AFB1. In addition to the reduction of AFB1–DNA adduct formation, the protective effect of ebselen against AFB1-induced oxidative DNA damage may also, at least in part, contribute to its anticarcinogenic property.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
S. T. Miorelli, R. M. Rosa, D. J. Moura, J. C. Rocha, L. A. Carneiro Lobo, J. A. Pegas Henriques, and J. Saffi
Antioxidant and anti-mutagenic effects of ebselen in yeast and in cultured mammalian V79 cells
Mutagenesis, March 1, 2008; 23(2): 93 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. B. Irmak, G. Ince, M. Ozturk, and R. Cetin-Atalay
Acquired Tolerance of Hepatocellular Carcinoma Cells to Selenium Deficiency: A Selective Survival Mechanism?
Cancer Res., October 15, 2003; 63(20): 6707 - 6715.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Nakamura, Q. Feng, T. Kumagai, K. Torikai, H. Ohigashi, T. Osawa, N. Noguchi, E. Niki, and K. Uchida
Ebselen, a Glutathione Peroxidase Mimetic Seleno-organic Compound, as a Multifunctional Antioxidant. IMPLICATION FOR INFLAMMATION-ASSOCIATED CARCINOGENESIS
J. Biol. Chem., January 18, 2002; 277(4): 2687 - 2694.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.